Apaxcel Life Sciences

Apaxcel Life Sciences is a San Diego-based biotechnology company focused on developing highly selective, small molecule inhibitors of the AXL receptor tyrosine kinase. The company's lead program, APX-801, is designed to address AXL-mediated resistance in various solid tumors, particularly in patients who have developed resistance to standard-of-care therapies like EGFR inhibitors. By targeting the AXL pathway, Apaxcel aims to restore sensitivity to existing treatments and improve outcomes for patients with aggressive, drug-resistant cancers. The company was founded by industry veterans with significant experience in oncology drug discovery and development.